We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
+5.31%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$999M
AUM Growth
+$357M
(+56%)
Cap. Flow
+$419M
Cap. Flow
% of AUM
41.94%
Top 10 Holdings %
Top 10 Hldgs %
54.5%
Holding
94
New
23
Increased
23
Reduced
18
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Smith & Nephew
SNN
|
+$20.4M |
| 2 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$20M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.3M |
| 4 |
Nurix Therapeutics
NRIX
|
+$14.5M |
| 5 |
Organogenesis Holdings
ORGO
|
+$14.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
+$12.7M |
| 2 |
NeoGenomics
NEO
|
+$9.19M |
| 3 |
CareDx
CDNA
|
+$8.03M |
| 4 |
Werewolf Therapeutics
HOWL
|
+$7.53M |
| 5 |
C4 Therapeutics
CCCC
|
+$7.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.82% |
| 2 | Financials | 0.64% |
| 3 | Consumer Staples | 0% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PVLA
51
Palvella Therapeutics
PVLA
$2.19B
| $2.6M | 0.26% |
8,593
-657
| -7% | -$210K |
|
52
Vanda Pharmaceuticals
VNDA
$312M
| $2.49M | 0.25% |
158,700
-139,900
| -47% | -$2.44M |
|
|
CCXI
53
DELISTED
ChemoCentryx, Inc.
CCXI
| $2.49M | 0.25% |
+68,320
| New | +$2.4M |
|
54
Viridian Therapeutics
VRDN
$2.43B
| $1.78M | 0.18% |
+90,000
| New | +$1.68M |
|
55
Immunic
IMUX
$194M
| $1.68M | 0.17% |
+17,500
| New | +$1.58M |
|
56
NovoCure
NVCR
$1.84B
| $1.67M | 0.17% |
22,275
-5,000
| -18% | -$502K |
|
57
CRISPR Therapeutics
CRSP
$5.05B
| $1.67M | 0.17% |
22,000
-70,214
| -76% | -$6.13M |
|
58
Avalo Therapeutics
AVTX
$973M
| $1.31M | 0.13% |
+267
| New | +$1.6M |
|
59
Liquidia Corp
LQDA
$7.93B
| $1.13M | 0.11% |
+231,485
| New | +$923K |
|
60
Arvinas
ARVN
$554M
| $904K | 0.09% |
+11,000
| New | +$895K |
|
|
61
Werewolf Therapeutics
HOWL
$19.5M
| $769K | 0.08% |
64,585
-498,811
| -89% | -$7.53M |
|
|
BCYC
62
Bicycle Therapeutics
BCYC
$276M
| $624K | 0.06% |
+10,250
| New | +$566K |
|
63
Fate Therapeutics
FATE
$288M
| $456K | 0.05% |
+7,800
| New | +$442K |
|
64
Celcuity
CELC
$4.51B
| $423K | 0.04% |
32,073
-51,615
| -62% | -$826K |
|
|
NGM
65
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $230K | 0.02% |
13,000
-28,000
| -68% | -$537K |
|
66
Beam Therapeutics
BEAM
$2.83B
| $227K | 0.02% |
2,850
-4,850
| -63% | -$415K |
|
|
LYRA
67
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $44K | ﹤0.01% |
200
-4,112
| -95% | -$1.32M |
|
68
Assembly Biosciences
ASMB
$525M
| – | – |
-93,500
| Closed | -$3.9M |
|
|
ATXS
69
DELISTED
Astria Therapeutics
ATXS
| – | – |
-112,499
| Closed | -$994K |
|
70
Atea Pharmaceuticals
AVIR
$389M
| – | – |
-117,600
| Closed | -$4.12M |
|
71
Axogen
AXGN
$2.39B
| – | – |
-158,140
| Closed | -$2.5M |
|
|
72
CareDx
CDNA
$2.35B
| – | – |
-126,661
| Closed | -$8.03M |
|
|
CMPS
73
Compass Pathways
CMPS
$1.82B
| – | – |
-127,743
| Closed | -$3.82M |
|
74
Corcept Therapeutics
CORT
$11.7B
| – | – |
-155,000
| Closed | -$3.05M |
|
75
CytomX Therapeutics
CTMX
$736M
| – | – |
-261,050
| Closed | -$1.33M |
|
Similar funds
TW
M
SG
BL
FFA
GWM
Q
SIM
Soleus Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Soleus Capital Management held 94 positions worth $999M, up 56% from $642M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Soleus Capital Management deployed $419M of net new capital in Q4 2021, opening 23 new positions and adding to 23 existing holdings. Its largest new stake was Smith & Nephew: 593,200 shares worth $20.5M.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 92% a quarter earlier, followed by Financials and Consumer Staples.
On the sell side, the largest reduction was Werewolf Therapeutics, an estimated $7.53M trimmed.
- Soleus Capital Management's largest Q4 2021 buy was Smith & Nephew: 593,200 shares worth $20.5M.
- Soleus Capital Management added most to Nurix Therapeutics in Q4 2021, an estimated $14.5M increase.
- Soleus Capital Management's biggest Q4 2021 reduction was Werewolf Therapeutics, cutting an estimated $7.53M.
- Soleus Capital Management fully exited Flexion Therapeutics, Inc. in Q4 2021, selling an estimated $12.7M.
- Soleus Capital Management's ten largest holdings make up 54% of its $999M portfolio in Q4 2021.
- Soleus Capital Management opened 23 new positions and closed 26 in Q4 2021.
- Soleus Capital Management's portfolio value rose 56% quarter-over-quarter to $999M.
Based on Soleus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.